Orrin Hatch actually said...

There are a lot of tradeoffs in the naming convention.

Is it possible for FDA to trace adverse events and identify the source without a unique identifier in the name?

I am concerned, as a taxpayer, with the breaches that we have had.

I believe the committee's report speaks for itself on this matter.